Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Food Allergy
NCT ID: NCT06380673
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
90 participants
INTERVENTIONAL
2024-04-22
2029-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy
NCT02379598
Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy
NCT01634490
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
NCT01998074
Tolerability of Hypoallergenic Formula in Children With Cow's Milk Allergy
NCT03909113
Growth, Safety and Tolerance of a Hydrolyzed Protein Infant Formula
NCT05618704
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When inclusion criteria are met and informed consent from the parents (and when old enough, assent from the children) is obtained, children will be included in the trial. During the inclusion visit an open 20' cooked milk oral food challenge (OFC) needs to be passed in the hospital. Each visit a validated pedQuality of life (QoL) questionnaire will be taken and blood will be drawn to determine baseline specific IgE (sIgE) and IgG4 to cow's milk. Subjects (n=75) are randomized in a 1/1/1 ratio across three arms for 12 months to study the arm's tolerance inducing capacity (see Arms and Interventions for more information). After 6 months patients are invited for an intermediate visit. After 12 months, a OFC with unheated milk will be performed in all children during their challenge visits. Three months after the OFC, the children will be invited for a termination visit. Children who did not pass the OFC with unheated cow's milk after 12 months, will be invited to an observational 48 months follow-up study, in order to later-on retrieve the potential moment of complete cow's milk tolerance induction by clinical files.
WP2: Study of the immunological mechanisms (Treg and Breg induction and switch to IgG4-producing B cells).
Venous blood will be taken from all 75 children recruited for WP1 at enrolment and at the challenge and termination visit and from 15 healthy age-matched children, after obtaining children's oral or written assent (where appropriate) and parent's informed consent. Peripheral blood mononuclear cells (PBMCs) will be isolated and stimulated by cow's milk proteins as well as a positive control. Membrane markers associated with regulatory activity on T cells will be studied by flow cytometry (FC), as well as cytokine production in the supernatant by meso scale discovery. Furthermore, B cells will be studied after PBMC stimulation by FC. Cow's milk specific IgG4 and cytokine production will also be studied in this culture supernatant.
WP3: In vitro BATs to mimic the outcome of OFC.
In vitro Basophil activation tests (BATs) will be fine-tuned by preparing extracts for 20', 15', 10', 5' cooked and fresh cow's milk. Fine-tuning will include the comparison of new protein extract batches with the first batches, the absence of background basophil activation upon contact with the lowest dose of allergen extract and the comparison of basophil activation of healthy and of allergic children in different phases of cow's milk tolerance, who should show differences depending on the grade of tolerance. After fine-tuning, BATs will be performed as described above with 3 (or 5) extracts from cow's milk at baseline, challenge visit and termination visit in all children recruited within the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stepwise introduction using gradually shorter heating of cow's milk proteins
Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.
Step 2: open introduction of 15' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.
Step 3: open introduction of 10' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.
Step 4: open introduction of 5' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 3 months.
Implementation of cow's milk in decreasingly heated forms
Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
Stepwise introduction using the Flemish Milk Ladder
The first 5 steps of the Flemish Milk Ladder (each containing a, b and c part) will be gradually introduced at home, each step for 21 days (2-3X a week during 3 consecutive weeks after which 3 days "rest"). We consider the 6th step the equivalent of tolerance induction so step 6 will be allowed once the OFC with uncooked milk is passed.
Implementation of cow's milk in decreasingly heated forms
Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
Control arm with introduction of 20' cooked cow's milk
Step 1: open introduction of 20' cooked cow's milk (at least 10 mL per portion, 2-3X a week) for 12 months.
Implementation of heated cow's milk
Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
Healthy age-matched subjects
For work package 2, 15 healthy age-matched subjects are included to compare immunological mechanisms with.
No intervention
Healthy subjects undergo no intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Implementation of cow's milk in decreasingly heated forms
Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
Implementation of heated cow's milk
Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
No intervention
Healthy subjects undergo no intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Children are at least 12 months old before introduction of heated cow's milk is considered.
* Children did not suffer from grade 4 anaphylaxis due to cow's milk-ingestion at presentation.
* Children have specific IgE levels to Bos d 8 below 1.2 kU/mL and/or children passed 20' cooked cow's milk provocation test executed on clinical judgement.
Exclusion Criteria
* Children are younger than 12 months old at the moment of passing 20' cooked cow's milk OFC.
* Parents are not able or not willing to adhere to a specific cow's milk protein-containing diet on a regular basis at home.
* Multiple food allergy, not compatible with any of the choices in the Flemish Milk Ladder.
* Parents and/or children are not willing to give IC/assent.
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dominque Bullens
Clinic Head in Pediatrics-Allergy at UZ Leuven, Head of the Allergy and Clinical Immunology Research group at KU Leuven (prof., dr.)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jasmine Leus, MD
Role: PRINCIPAL_INVESTIGATOR
Maria Middelares Hospital, Gent
Katrien Coppens, MD
Role: PRINCIPAL_INVESTIGATOR
Imelda Hospital, Bonheiden
Sophie Verelst, MD
Role: PRINCIPAL_INVESTIGATOR
KU Leuven and Jessa Hospital, Hasselt
Kate Sauer, MD
Role: PRINCIPAL_INVESTIGATOR
AZ Sint-Jan AV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Imelda Hospital Bonheiden
Bonheiden, , Belgium
AZ Sint-Jan
Bruges, , Belgium
AZ Maria Middelares
Ghent, , Belgium
Jessa Hospital
Hasselt, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Katrien Coppens, MD
Role: primary
Kate Sauer, MD
Role: primary
Jasmine Leus, MD
Role: primary
Sophie Verelst, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
s68299
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.